Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects With Prurigo Nodularis

Next Previous
Search
Trial Profile

A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects With Prurigo Nodularis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vixarelimab (Primary)
  • Indications Prurigo nodularis; Pruritus
  • Focus Therapeutic Use
  • Sponsors Kiniksa Pharmaceuticals

Most Recent Events

  • 22 Sep 2023 Status changed from active, no longer recruiting to completed.
  • 26 Sep 2022 Planned End Date changed from 30 Jul 2023 to 1 Aug 2023.
  • 26 Sep 2022 Planned primary completion date changed from 30 Nov 2022 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top